AR084333A1 - miARN EN ENFERMEDADES ARTICULARES - Google Patents

miARN EN ENFERMEDADES ARTICULARES

Info

Publication number
AR084333A1
AR084333A1 ARP110104736A ARP110104736A AR084333A1 AR 084333 A1 AR084333 A1 AR 084333A1 AR P110104736 A ARP110104736 A AR P110104736A AR P110104736 A ARP110104736 A AR P110104736A AR 084333 A1 AR084333 A1 AR 084333A1
Authority
AR
Argentina
Prior art keywords
mirna
disease
articular diseases
treatment
articular
Prior art date
Application number
ARP110104736A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR084333A1 publication Critical patent/AR084333A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a microARN (miARN), en particular mir-140, como un indicador del estado de un tejido o una enfermedad tal como osteoartritis (OA) y como molécula diana para el descubrimiento de una sustancia para el tratamiento de una enfermedad articular. También se proporcionan métodos y compuestos para investigación, análisis y/o tratamiento de una enfermedad articular, especialmente OA.
ARP110104736A 2010-12-17 2011-12-16 miARN EN ENFERMEDADES ARTICULARES AR084333A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10306444 2010-12-17

Publications (1)

Publication Number Publication Date
AR084333A1 true AR084333A1 (es) 2013-05-08

Family

ID=45446007

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104736A AR084333A1 (es) 2010-12-17 2011-12-16 miARN EN ENFERMEDADES ARTICULARES

Country Status (3)

Country Link
AR (1) AR084333A1 (es)
TW (1) TW201241179A (es)
WO (1) WO2012084709A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106119375B (zh) * 2016-07-05 2019-12-06 四川大学华西医院 一种对关节软骨退变的调控作用的药物及验证方法
US20240200064A1 (en) * 2021-04-13 2024-06-20 Oslo Universitetssykehus Hf Gene therapy for inflammatory conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
DE69415343T2 (de) 1993-10-27 1999-08-26 Ribozyme Pharmaceuticals 2'-amido-und 2'-peptido-modifizierte oligonukleotide
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
GB9602326D0 (en) 1996-02-06 1996-04-03 Cruachem Ltd Compounds
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
WO1997035564A1 (de) 1996-03-25 1997-10-02 Lts Lohmann Therapie-Systeme Gmbh Transdermales therapeutisches system mit geringer applikationsdicke und hoher flexibilität sowie herstellungsverfahren
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
WO1998037240A1 (en) 1997-02-24 1998-08-27 Tm Technologies, Inc. Anti-sense oligonucleotide pharmacological agents
WO2004076622A2 (en) * 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
WO2010108192A1 (en) * 2009-03-20 2010-09-23 The Research Foundation Of State University Of New York Mirnas as therapeutic targets in cancer

Also Published As

Publication number Publication date
TW201241179A (en) 2012-10-16
WO2012084709A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
AR083715A1 (es) Composiciones y metodos para la distribucion selectiva de moleculas de oligonucleotidos a tipos especificos de neuronas
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
BR112015011118A2 (pt) conjugado; composição farmacêutica; e uso de um ou mais dos conjugados
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CO6501131A2 (es) Antagonistas de espiro-oxindol de mdm2
EA201590115A8 (ru) Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
AR088514A1 (es) Inmunoligantes biespecificos dirigidos contra tnf
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
CR20140255A (es) Derivados de los nucleósidos sustituidos en 4'-azido, 3'-fluoro como inhibidores de la replicación del rna del vhc
EA201101330A1 (ru) Замещенные пиримидины, предназначенные для лечения рака
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
SV2009003435A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea
AR080680A1 (es) Proteinas de union a basigina
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
AR084331A1 (es) microARN (miARN) EN ENFERMEDADES ARTICULARES
AR068574A1 (es) Metodos para esterilizar lentes oftalmicas
AR084332A1 (es) miRNA EN ARTROPATIA
AR084333A1 (es) miARN EN ENFERMEDADES ARTICULARES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal